Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Receivables came in at $11.9 million in Q1 2026, down 54.92% YoY from $26.3 million in Q1 2025, and down 69.23% on a QoQ basis from $38.5 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Receivables data on file, last reported at $11.9 million in Q1 2026.
- Quarterly Receivables fell 54.92% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 54.92% YoY) and the FY2025 annual result came in at $38.5 million, up 224.13% from the prior year.
- Receivables fell to $11.9 million in Q1 2026, from $38.5 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $178.1 million in Q2 2022 to a low of $899000.0 in Q2 2023.
- A 5-year average of $45.1 million and a median of $24.2 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables slumped 99.5% — and 2024, when it surged 1134.93%.
- Tracing DNA's Receivables over 5 years: stood at $1.6 million in 2022, then surged by 595.89% to $10.8 million in 2023, then climbed by 9.63% to $11.9 million in 2024, then jumped by 224.13% to $38.5 million in 2025, then tumbled by 69.23% to $11.9 million in 2026.
- The last three Receivables figures came in at $11.9 million (Q1 2026), $38.5 million (Q4 2025), and $32.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 20.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.41 Mn |
| Mar 31, 2026 | 11.85 Mn |
| Dec 31, 2025 | 38.53 Mn |
| Sep 30, 2025 | 32.63 Mn |
| Jun 30, 2025 | 33.05 Mn |
| Mar 31, 2025 | 26.29 Mn |
| Dec 31, 2024 | 11.89 Mn |
| Sep 30, 2024 | 8.63 Mn |
| Jun 30, 2024 | 11.10 Mn |
| Mar 31, 2024 | 24.19 Mn |
| Dec 31, 2023 | 10.84 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 899,000.00 |
| Mar 31, 2023 | 84.84 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 119.84 Mn |
| Jun 30, 2022 | 178.12 Mn |
| Mar 31, 2022 | 171.07 Mn |
| Dec 31, 2021 | 4.60 Mn |
| Sep 30, 2021 | 50.73 Mn |